Intravenous magnesium sulfate for bronchial hyperreactivity: a randomized, controlled, double-blind study.

Area of Science:

• Pulmonology
• Clinical Pharmacology

Background:

• Magnesium's role in acute asthma exacerbations is recognized, but its impact on bronchial hyperreactivity remains debated.
• Existing research presents conflicting data regarding magnesium's effects on bronchial hyperreactivity.

Purpose of the Study:

• To investigate the efficacy of intravenous magnesium sulfate in mitigating bronchial hyperreactivity.
• To assess the impact of magnesium on methacholine-induced bronchoconstriction.

Main Methods:

• A randomized, double-blind, placebo-controlled trial was conducted with 30 subjects exhibiting bronchial hyperreactivity.
• Participants received either intravenous magnesium sulfate (0.3 mmol/kg/h) or a placebo (normal saline).
• Bronchial reactivity to methacholine was measured at baseline and post-infusion using the provocative dose (PC20) to decrease forced expiratory volume in 1 second by 20%.

Main Results:

• The magnesium group showed a significantly greater increase in the provocative dose of methacholine (PC20) compared to the placebo group (0.48 vs. 0.05 mg/mL, P = .028).
• In the magnesium group, PC20 significantly increased from baseline (0.83 to 1.31 mg/mL, P = .0001).
• No significant change in PC20 was observed in the placebo group (0.86 to 0.91 mg/mL, P = .83).

Conclusions:

• Intravenous magnesium sulfate administration led to a significant improvement in bronchial hyperreactivity.
• A higher proportion of subjects in the magnesium group achieved normal PC20 levels (30%) compared to the placebo group (10%).
• Intravenous magnesium sulfate may serve as an effective adjunct therapy for managing bronchial hyperreactivity in asthma patients.